SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: celeryroot.com who wrote (24416)8/12/1998 2:08:00 PM
From: Henry Niman  Respond to of 32384
 
Per LGND's 1997 (and earlier) Annual Reports, Lloyd Flanders is (was) a "Senior Vice President, Preclinical Development and R&D Project Manager". He is no longer with Ligand and I believe that he left right after the delayed NDA filing for topical Panretin. I suspect that there may have been a relationship the delay of the filing, and his departure, but I have no details.

I did ask SA last week about his recent sale of stock, and as I suspected, she confirmed that he was no longer with LGND and had to exercise options within 90 days, hence the sale of some (all?) of his holdings.



To: celeryroot.com who wrote (24416)8/12/1998 2:12:00 PM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
I'm not sure why Comtrex called him an "affiliate":
News July 30, 16:12 Eastern Time

LIGAND AFFILIATE FILES FORM 144, TO SELL SHARES

WASHINGTON, DC, Jul. 30, 1998 (States) -- Lloyd Flanders, an affiliate of Ligand Pharmaceuticals, Inc. of San Diego, Calif., reported on July 27, 1998, the proposed sale of 28,263 shares on July 22, 1998, for $342, 688 through Smith Barney.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News